Evidence map›Paper›PMID 36899890›Full record

ArticleCells2023

Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer.

Diane Frankel, Isabelle Nanni, L'Houcine Ouafik, Laurent Greillier, Hervé Dutau, Philippe Astoul, Laurent Daniel, Elise Kaspi, Patrice Roll

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Diane FrankelAix Marseille University, APHM, INSERM, MMG, la Timone Hospital, Cell Biology Laboratory, 13005 Marseille, France.ORCID 0000-0003-3321-6951
Isabelle NanniAix Marseille University, APHM, CHU Nord, Oncobiology Laboratory, 13015 Marseille, France.
L'Houcine OuafikAix Marseille University, APHM, CHU Nord, Oncobiology Laboratory, 13015 Marseille, France.
Laurent GreillierMultidisciplinary Oncology and Therapeutic Innovations, Marseille University Hospital, APHM, 13015 Marseille, France.ORCID 0000-0002-5807-9503
Hervé DutauDepartment of Thoracic Oncology, Pleural Diseases and Interventional Pulmonology, APHM, 13015 Marseille, France.
Philippe AstoulDepartment of Thoracic Oncology, Pleural Diseases and Interventional Pulmonology, APHM, 13015 Marseille, France.ORCID 0000-0003-3988-1792
Laurent DanielAix Marseille University, APHM, Anatomopathology Department, 13005 Marseille, France.
Elise KaspiAix Marseille University, APHM, INSERM, MMG, la Timone Hospital, Cell Biology Laboratory, 13005 Marseille, France.ORCID 0000-0003-0458-5109
Patrice RollAix Marseille University, APHM, INSERM, MMG, la Timone Hospital, Cell Biology Laboratory, 13005 Marseille, France.ORCID 0000-0002-0045-5641
Inserm · FRAix-Marseille Université · FRAssistance Publique Hôpitaux de Marseille · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer has become the leading cause of cancer death for men and women. Most patients are diagnosed at an advanced stage when surgery is no longer a therapeutic option. At this stage, cytological samples are often the less invasive source for diagnosis and the determination of predictive markers. We assessed the ability of cytological samples to perform diagnosis, and to establish molecular profile and PD-L1 expression, which are essential for the therapeutic management of patients.

methodsWe included 259 cytological samples with suspected tumor cells and assessed the ability to confirm the type of malignancy by immunocytochemistry. We summarized results of molecular testing by next generation sequencing (NGS) and PD-L1 expression from these samples. Finally, we analyzed the impact of these results in the patient management.

resultsAmong the 259 cytological samples, 189 concerned lung cancers. Of these, immunocytochemistry confirmed the diagnosis in 95%. Molecular testing by NGS was obtained in 93% of lung adenocarcinomas and non-small cell lung cancer. PD-L1 results were obtained in 75% of patients tested. The results obtained with cytological samples led to a therapeutic decision in 87% of patients.

conclusionCytological samples are obtained by minimally invasive procedures and can provide enough material for the diagnosis and therapeutic management in lung cancer patients.

Indexed as

Adenocarcinoma of LungCarcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenFemaleHumansImmunohistochemistryMaleB7-H1 Antigenadenocarcinomacytological samplecytopathologyimmunocytochemistrylung cancermolecular testingNGSPD-L1

Identifiers

PMID36899890
PMCPMC10001120
OpenAlexW4322501089

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read56
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.